Bilateral severe fibrinous anterior uveitis--an unusual complication of pamidronate therapy exacerbated by topical latanoprost.
OBJECTIVE
The aim of this study was to report a case of severe bilateral fibrinous anterior uveitis following pamidronate therapy in a patient on latanoprost.


METHODS
This study is presented as an interventional case report.


RESULTS
Clinical examination showed bilateral severe fibrinous uveitis following an intravenous infusion of disodium pamidronate. Ocular signs and symptoms responded to stopping latanoprost and treatment with oral prednisolone (60 mg) and hourly topical prednisolone acetate 1%. The reintroduction of latanoprost resulted in a recurrence, which was stopped with subsequent improvement.


CONCLUSIONS
Mild anterior uveitis is an unfamiliar adverse effect of pamidronate therapy. However, severe fibrinous uveitis has not been previously described. This may be due to the compounding effect of latanoprost. This case highlights the importance of history taking and awareness of the otherwise uncommon side effect of this commonly prescribed medication.
Ramasamy
Balasubramanian
B
Department of Ophthalmology, North Cheshire Hospitals NHS Trust, Warrington Hospital, Warrington, United Kingdom. ram_b_sam@hotmail.com
Quah
Sayaun
S
Sahni
Jayashree N
JN
Palimar
Prasad
P
D000208:Acute Disease; D000287:Administration, Topical; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D005337:Fibrin; D005902:Glaucoma, Open-Angle / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D000077338:Latanoprost; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy; D000077268:Pamidronate; D011239:Prednisolone / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D005337:Fibrin; D011239:Prednisolone; D000077268:Pamidronate